Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
  1. Home
  2. Publications
  3. Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial

Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial

Authors:
  • JXJie Xu
    Jie Xu
  • LXLu Xie
    Lu Xie
  • XSXin Sun
    Xin Sun
  • KLKuisheng Liu
    Kuisheng Liu
  • XLXin Liang
    Xin Liang
  • ZCZhenyu Cai
    Zhenyu Cai
  • XTXiaodong Tang
    Xiaodong Tang
  • WGWei Guo
    Wei Guo

Open Access
Publisher website
Google Scholar
  • 1 April 2023
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.22490804
Abstract
Representativeness of Study Participants
Keywords
  • TABLE S2
  • LONGER
  • SUPPLEMENTARY TABLE
  • CONTROLLED PHASE
  • SHORTER SCHEDULES
  • EWING SARCOMA
  • STUDY PARTICIPANTS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.